News

In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.

Marc S. Ernstoff, MD, discusses metastatic melanoma and how patients may be managed.

The FDA has not made a decision on the approval application for toripalimab plus chemotherapy or toripalimab monotherapy for the treatment of advanced recurrent or metastatic nasopharyngeal carcinoma.

In an interview with Targeted Oncology, Jimmy Caudell, MD, PhD, discussed the biggest challenges being faced in the head and neck cancer space.

Michael Chuong, MD, discusses the study design of a trial evaluating radiation therapy in patients with locally advanced pancreatic cancer.

The Association of Community Cancer Centers is announcing the release of a new tool intended to facilitate education and adoption of new clinical and technological advancements in diagnosis, staging, and treatment of cancer.

The Association of Community Cancer Centers (ACCC) is grateful that Congress is poised to address many of our year-end policy priorities in its proposed fiscal year 2023 omnibus appropriations package released this week

Allan Pickens, MD, discusses the current treatment landscape for esophageal cancer.

In the pivotal phase 2 GO29781 study, the objective response rate and response durability was high, leading to the FDA approval of mosunetuzumab for the treatment of relapsed or refractory follicular lymphoma.

In an interview with Targeted Oncology, Marc S. Ernstoff, MD, discusses recent updates in the management of metastatic melanoma.

In an interview with Targeted Oncology, Allan Pickens, MD, discussed research on racial disparities in surgery for esophageal cancer.

New published findings from the phase 1/2 KRYSTAL-1 study have caught the attention for the FDA.

In an early-intervention lung screening program, patients with lung cancer were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.

Florida Cancer Specialists & Research Institute welcomes Board-certified medical oncologist/hematologist Madhu Unnikrishnan, MD.

Jimmy Caudell, MD, PhD, discusses the overall incidence of human papillomavirus-positive and negative oropharyngeal cancers in the United States.

Stringent and dedicated interventions are necessary to handle the spread of COVID-19, as this represents a major healthcare challenge for humanity, says Daniel Vorobiof, MD.

Data from patients with non–small cell lung cancer in the United States are adjustable to approximate overall survival in selected populations of Canadian patients

American Oncology Network, LLC announced today Brad Prechtl’s retirement as President and Chief Development Officer effective January 1, 2023.

In a retrospective study, investigators assessed the risk of development a malignancy in patients with psoriasis. Findings showed that select patients with psoriasis have a higher risk cancer risk.

VIKTORIA-1 is a phase 3 study evaluating treatment with gedatolisib plus fulvestrant with or without palbociclib in patients with HR-positive, HER-negative breast cancer.

Florida Cancer Specialists & Research Institute participated in the phase 3 POSEIDON, which led to FDA approval of a new immunotherapy that improves chemotherapy treatment for metastatic non small cell lung cancer.

Florida Cancer Specialists & Research Institute, welcomes Robert Ferdman, MD to the statewide practice.

In an interview with Targeted Oncology, Jay W. Granzow, MD, discussed the diagnosis and early detection of patients with cancer-related secondary lymphedema.

Following impressive data presented at the ASH Annual Meeting, the FDA granted approval to olutasidenib or the treatment of patients with treatment-naïve and relapsed or refractory acute myeloid leukemia.

In an interview with Targeted Oncology, Channing J. Paller, MD, discussed the current approaches to radiation therapy, androgen deprivation therapy, and molecular imaging for men with prostate cancer who have biochemical recurrence.

The combination of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is moving into the frontline setting for patients with diffuse large B-cell lymphoma.

One of the most promising innovations in the multiple myeloma space has been the development of bispecific antibodies.

Treatment with CD19-/CD22-chimeric antigen T-cell therapy demonstrated durable remissions in children with relapsed or refractory B-acute lymphoblastic leukemia, according to a phase 2 study.

For patients with locally advanced or metastatic urothelial cancer, the FDA has accepted for priority review supplemental biologics license applications for enfortumab vedotin-ejfv and pembrolizumab.

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the findings from the ELAINE-1 trial.